
CLAIMS

1. A compound of formula (I) or a salt thereof



(I)

where

R^1 is C_{1-3}alkyl;

R^2 is $-NR^{2a}R^{2a'}$ or $-OR^{2b}$;

wherein one of R^{2a} or $R^{2'a}$ is hydrogen, and R^{2b} or the other of R^{2a} or $R^{2'a}$ is selected from C_{1-6}alkyl, haloC_{1-6}alkyl, $R^{2c}R^{2'c}N$-C_{1-6}alkyl, carbocyclyl, carbocyclylC_{1-4}alkyl, heterocyclyl and heterocyclylC_{1-4}alkyl,

wherein any of the carbocyclyl or heterocyclyl groups are optionally substituted by one or more groups selected from halogen, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, carbonyl, -CO-carbocyclyl, azido, amino, hydroxyl, nitro and cyano, wherein the -CO-carbocyclyl group may be optionally substituted by one or more groups selected from halogen, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, azido, nitro and cyano;

or two adjacent groups on any of the carbocyclyl or heterocyclyl groups together with the interconnecting atoms form a 5- or 6-membered ring which ring may contain 1 or 2 heteroatoms independently selected from O, S and N; or R^{2a} and $R^{2'a}$ together with the N-atom to which they are attached form a 4-, 5-, 6- or 7-membered ring which optionally contains 1 or 2 heteroatoms independently selected from O, S and N; wherein the 4-, 5-, 6- or 7-membered ring is optionally substituted by C_{1-6}alkyl, hydroxyl or amino;

R^{2c} and $R^{2'c}$ are independently hydrogen or C_{1-6}alkyl;

each R^3 is independently selected from hydrogen, hydroxyl, halo, C_{1-6}alkyl, halo C_{1-6}alkyl, C_{1-6}alkoxy, halo C_{1-6}alkoxy, nitro, cyano, CF_3, $-OCF_3$, $-COOR^5$, $-C_{1-4}$alkylNR^6R^7 and -C_{1-4}alkylOH;

R^4 is hydroxyl, halo, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, nitro, cyano, CF_3, $-OCF_3$, $-COOR^5$; or $-OS(O)_2C_{1-4}$alkyl;

R^5 is C_{1-3}alkyl; and

n is an integer 1 to 5.

2. A compound or a salt thereof according to claim 1, wherein R^1 is methyl.

3. A compound or a salt thereof according to claim 1 or claim 2, wherein R^2 is $-OR^{2b}$.

4. A compound or a salt thereof according to claim 3, wherein R^{2b} is C_{1-6}alkyl.

5. A compound or a salt thereof according to claim 4, wherein R^{2b} is selected from methyl, ethyl, isopropyl and butyl.

6. A compound or a salt thereof according to claim 1 or claim 2, wherein R^2 is $-NR^{2a}R^{2a'}$.

7. A compound or a salt thereof according to claim 6, wherein R^{2a} is hydrogen and $R^{2'a}$ is C_{1-6}alkyl.

8. A compound or a salt thereof according to claim 7, wherein $R^{2'a}$ is ethyl.

9. A compound or a salt thereof according to claim 6, wherein R^{2a} is hydrogen and $R^{2'a}$ is $R^{2c}R^{2'c}N$-C_{1-6}alkyl.

10. A compound or a salt thereof according to claim 9 wherein $R^{2'a}$ is selected from $R^{2c}R^{2'c}N$-CH_2-, $R^{2c}R^{2'c}N$-CH_2CH_2-, $R^{2c}R^{2'c}N$-$CH_2CH_2CH_2$- and $R^{2c}R^{2'c}N$-$CH_2CH_2CH_2CH_2$-.

11. A compound or a salt thereof according to claim 10, wherein R^{2c} and $R^{2'c}$ are selected from hydrogen and methyl.


12. A compound or a salt thereof according to claim 6, wherein R^{2a} is hydrogen and $R^{2'a}$ is carbocyclyl.

13. A compound or a salt thereof according to claim 12, wherein $R^{2'a}$ is cyclopentyl or cyclohexyl, wherein each group is optionally substituted once by amino or hydroxyl.

14. A compound or a salt thereof according to claim 6, wherein R^{2a} is hydrogen and $R^{2'a}$ is heterocyclyl.

15. A compound or a salt thereof according to claim 14, wherein $R^{2'a}$ is selected from pyrrolidinyl, piperidinyl, tetrahydrofuranyl and tetrahydropyran, wherein each group is optionally substituted by C_{1-6}alkyl.

16. A compound or a salt thereof according to claim 15, wherein $R^{2'a}$ is selected from:



; ; ; ; ; ; ; ; and .


17. A compound or a salt thereof according to claim 6, wherein R^{2a} is hydrogen and $R^{2'a}$ is heterocyclylC_{1-4}alkyl, wherein the heterocyclyl is optionally substituted once by amino, hydroxyl or methyl.

18. A compound or a salt thereof according to claim 17 wherein $R^{2'a}$ is selected from heterocyclyl-CH_2-, heterocyclyl-CH_2CH_2-, heterocyclyl-$CH_2CH_2CH_2$- and heterocyclyl-$CH_2CH_2CH_2CH_2$-, wherein the heterocyclyl is optionally substituted once by amino, hydroxyl or methyl.

19. A compound or a salt thereof according to claim 18, wherein heterocyclyl is selected from tetrahydrofuranyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, piperazinyl, morpholino

and thiomorpholinodioxide, wherein each group is optionally substituted once by amino, hydroxyl or methyl.

20. A compound or a salt thereof according to claim 19, wherein heterocyclyl is selected from:



21. A compound or a salt thereof according to any one of claims 1 – 20, in which n is 1.

22. A compound or a salt thereof according to any one of claims 1 – 21, in which R^3 is 3-fluoro, 4-chloro, 4-fluoro, 4-methoxy or 4-CF_3.

23. A compound or a salt thereof according to claim 22, in which R^3 is 4-chloro.

24. A compound or a salt thereof according to any one of claims 1 – 23, wherein R^4 is MeO.

25. A compound or a salt thereof according to claim 24, wherein R^4 is 8-MeO.

26. A compound or a salt thereof according to any one of claims 1– 25 which is the S-enantiomer.


27. A compound which is any one of Examples 1 – 37 or a salt thereof.

28. A compound which is Example 38 or Example 39 or a salt thereof.

29. A compound which is any one of Examples 40 – 48 or a salt thereof.

30. A compound which is any one of Examples 49 – 82 or a salt thereof.

31. A compound which is 2-[(4*S*)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepin-4-yl]-*N*-ethylacetamide



or a salt thereof.

32. A compound according to any one of claims 1 – 31, or a pharmaceutically acceptable salt thereof.

33. A pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 32 and one or more pharmaceutically acceptable carriers, diluents or excipients.

34. A combination pharmaceutical product comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 32 together with one or more other therapeutically active agents.

35. A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 32, for use in therapy.

36. A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 32, for use in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

37. A compound or a pharmaceutically acceptable salt thereof for use according to claim 36, wherein the disease or condition is a chronic autoimmune and/or inflammatory condition.

38. A compound or a pharmaceutically acceptable salt thereof for use according to claim 36, wherein the disease or condition is cancer.

39. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 32, in the manufacture of a medicament for the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

40. A use according to claim 39, wherein the disease or condition is a chronic autoimmune and/or inflammatory condition.


41. A use according to claim 39, wherein the disease or condition is cancer.

42. A use according to any one of claims 39 to 41, wherein the subject is a human.

43. A use according to any one of claims 39 to 42, wherein said medicament is to be contacted with the bromodomain.

CLAIMS

1. A compound of formula (Ic) or a pharmaceutical acceptable salt thereof



(Ic)

where

R^1 is C_{1-3}alkyl;

R^2 is $-NR^{2a}R^{2a'}$ or $-OR^{2b}$;

wherein one of R^{2a} or $R^{2'a}$ is H, and R^{2b} or the other of R^{2a} or $R^{2'a}$ is selected from C_{1-6}alkyl, haloC_{1-6}alkyl, $R^{2c}R^{2'c}$N-C_{1-6}alkyl, carbocyclyl, carbocyclylC_{1-4}alkyl, heterocyclyl and heterocyclylC_{1-4}alkyl,

wherein any of the carbocyclyl or heterocyclyl groups are optionally substituted by one or more groups selected from halogen, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, carbonyl, -CO-carbocyclyl, azido, nitro and cyano,

wherein the -CO-carbocyclyl group may be further optionally substituted by one or more groups selected from halogen, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, azido, nitro and cyano;

or two adjacent groups on any of the carbocyclyl or heterocyclyl groups together with the interconnecting atoms form a 5- or 6-membered ring which ring may contain 1 or 2 heteroatoms independently selected from O, S and N;

or R^{2a} and $R^{2'a}$ together with the N-atom to which they are attached form a 5-, 6- or 7-membered ring which may optionally contain 1 or 2 heteroatoms independently selected from O, S and N; wherein the 5-, 6- or 7-membered ring may be further optionally substituted by C_{1-6}alkyl;

R^{2c} and $R^{2'c}$ are independently H and C_{1-6}alkyl;

each R^3 is independently selected from H, hydroxy, halo, C_{1-6}alkyl, halo C_{1-6}alkyl, C_{1-6}alkoxy, halo C_{1-6}alkoxy, nitro, cyano, CF_3, $-OCF_3$ and $-COOR^5$;


R^4 is hydroxy, halo, C_{1-6}alkyl, halo C_{1-6}alkyl, C_{1-6}alkoxy, halo C_{1-6}alkoxy, nitro, cyano, CF_3, $-OCF_3$; $-COOR^5$ or $-OS(O)_2C_{1-4}$alkyl;

R^5 is C_{1-3}alkyl; and

n is an integer 1 to 5 for use in the treatment of cancer,

2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof in which R^4 represents hydroxyl or C_{1-6}alkoxy.

3. A compound according to claim 1 or a pharmaceutical acceptable salt thereof which is a compound of formula (Ib)



(Ib)

wherein:

R^1, R^2 and R^3 and n are as defined in claim 1.

4. A compound or a pharmaceutically acceptable salt thereof according to any one of claim 1 – 3 wherein R^1 is methyl.

5. A compound or a pharmaceutically acceptable salt thereof according to any one of claim 1 – 4 in which n is 1.

6. A compound or a pharmaceutically acceptable salt thereof according to any one of claim 1 – 5 wherein R^3 is 3-fluoro, 4-chloro, 4-fluoro, 4-methoxy or 4-CF_3.

7. A compound or a pharmaceutically acceptable salt thereof according to any one of claim 1 – 6 which is the S-enantiomer.

8. A compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 – 7 wherein the cancer is selected from hematological, epithelial including lung, breast and colon carcinomas, mesenchymal, hepatic, renal and neurological tumours.

9. The use of a compound or a pharmaceutical acceptable salt thereof as defined in any one of claims 1 - 7 in the manufacture of a medicament for the treatment of cancer.

10. The use according to claim 9, wherein the cancer is selected from hematological, epithelial including lung, breast and colon carcinomas, mesenchymal, hepatic, renal and neurological tumours.